Accuray April 23rd, 2024
April 23rd, 2024, 8.30am EST | 2.30pm CEST | 8.30pm HKT
Presenter: Yuan Zhi Yong, M.D., Professor, Chair of Radiation Oncology Department, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Moderator: Joost J. Nuyttens, M.D., Ph.D., Radiation Oncologist, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Summary:
For patients who are medically inoperable and have central or ultra-central lung cancer (CLC/UCLC), treatment options can be limited. However, in recent years, stereotactic ablative radiotherapy (SABR) or stereotactic body radiotherapy (SBRT) has improved the clinical efficacy and survival rate of CLC/UCLC patients. Despite this progress, the appropriate radiation therapy dosage remains a topic of debate.
Over the past decade, the Tianjin Medical University Cancer Institute & Hospital has conducted extensive research into the clinical application of SBRT for CLC/UCLC patients. Their findings may provide valuable insight into managing these patients. In this upcoming webinar, Dr. Yuan will share their experience and results of SBRT for CLC/UCLC in Non-Small Cell Lung Cancer
This webinar is pending approval from CAMPEP for 1 MPCEC hour and approved by ASRT for 1 category A credit.